NAMS

NewAmsterdam Pharma Company N.V. Ordinary Shares

HealthcareBiotechnologyNetherlandsNASDAQ

$30.75

+2.86%today

MKT CAP

$3.5B

-12.5% · 1Y

Full Financials

Trailing P/E-

Forward P/E-25.4x

EV/EBITDA-

Price/Sales-

Dividend Yield-

Revenue Growth YoY-

Earnings Growth YoY-

Revenue Growth QoQ-91.1%

5y Revenue CAGR-42.0%

5y Earnings CAGR-

Gross Margin-

Operating Margin-

Net Margin-

ROE-

Debt / Equity-

Free Cash Flow-

Insider Ownership1.0%

Institutional Ownership115.3%

Short % of Float7.94%

Days to Cover8.9d

1 Week+4.5%

1 Month-

3 Months-

6 Months-

YTD-

1 Year-

3 Years-

5 Years-

vs 50-day SMA-

vs 200-day SMA-

vs 52w High-

vs 52w Low-

Peers

Ticker	Cap	Score	P/E	Fwd P/E	EV/EBITDA	ROE	Gross	D/E	Div
PTGX Protagonist Therapeutics Inc. Common Stock	$6.6B	5	-	-	-	-	-	-	0.00%
CELC Celcuity Inc. Common Stock	$6.7B	5	-	-	-	-	-	-	0.00%
ACLX Arcellx Inc. Common Stock	$6.7B	5	-	-	-	-	-	-	-
KYMR Kymera Therapeutics Inc. Common Stock	$7.0B	-	-	-	-	-27.1%	0%	5.23	0.00%
TECH Bio-Techne Corp Common Stock	$7.1B	36	72.7	24.4	-	-	-	-	63.00%
HALO Halozyme Therapeutics Inc. Common Stock	$7.9B	73	25.5	6.6	-	-	-	-	0.00%